Please login to the form below

Not currently logged in
Email:
Password:

aTyr appoints rare disease expert as president

Frederic Chereau has senior experience at Shire and Genzyme

US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.

Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company's cardiovascular business.

He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.

Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau's appointment will guide the company's “global outreach and strategic partnerships”.

7th February 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics